BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.
Bright Green (Nasdaq: BGXX) has signed a letter of intent to supply DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a leader in pharmaceutical cannabinoids and psychedelic molecules. This partnership aims to produce domestically manufactured cGMP pharmaceutical-grade Active Pharmaceutical Ingredients (APIs) for US and global markets. Bright Green is positioning itself as a leading domestic supplier of DEA-controlled, plant-based raw materials for cannabinoid, psychedelic, and opioid-based drugs in the USA.
The company recently passed the DEA's annual operational procedures for Schedule I & II drug cultivation and manufacturing, bringing it closer to beginning operations. With new fundraising and supply agreements in progress, Bright Green anticipates a strong performance in 2025.
Bright Green (Nasdaq: BGXX) ha firmato una lettera di intenti per fornire estratti di marijuana approvati dalla DEA e psichedelici di origine vegetale a Benuvia Operations, leader nel settore dei cannabinoidi farmaceutici e delle molecole psichedeliche. Questa partnership ha come obiettivo la produzione di Ingredienti Farmaceutici Attivi (API) di grado farmaceutico cGMP prodotti a livello nazionale per i mercati statunitensi e globali. Bright Green si sta posizionando come fornitore nazionale leader di materie prime vegetali controllate dalla DEA per farmaci a base di cannabinoidi, psichedelici e oppioidi negli USA.
L'azienda ha recentemente superato le procedure operative annuali della DEA per la coltivazione e produzione di farmaci di Categoria I e II, avvicinandosi così all'inizio delle operazioni. Con nuovi accordi di finanziamento e fornitura in corso, Bright Green prevede una forte performance nel 2025.
Bright Green (Nasdaq: BGXX) ha firmado una carta de intenciones para suministrar extractos de marihuana aprobados por la DEA y psicodélicos de origen vegetal a Benuvia Operations, líder en cannabinoides farmacéuticos y moléculas psicodélicas. Esta asociación tiene como objetivo la producción de Ingredientes Farmacéuticos Activos (API) de grado farmacéutico cGMP fabricados a nivel nacional para los mercados de EE.UU. y globales. Bright Green se está posicionando como un proveedor nacional líder de materias primas de origen vegetal controladas por la DEA para medicamentos basados en cannabinoides, psicodélicos y opioides en EE. UU.
La empresa recientemente aprobó los procedimientos operativos anuales de la DEA para el cultivo y manufactura de drogas de la Lista I y II, acercándose así a comenzar sus operaciones. Con nuevos acuerdos de financiamiento y suministro en marcha, Bright Green anticipa un fuerte rendimiento en 2025.
Bright Green (Nasdaq: BGXX)는 Benuvia Operations에 DEA 승인 대마추출물 및 식물 기반 정신 약품을 공급하기 위한 의향서에 서명했습니다. 이 파트너십은 미국 및 글로벌 시장을 위한 국내 제조 cGMP 제약 급 활성 제약 성분(API) 생산을 목표로 하고 있습니다. Bright Green은 미국에서의 카나비노이드, 정신 약품 및 오피오이드 기반 약물에 필요한 DEA 통제 식물 기반 원료의 주요 국내 공급업체로 자리잡고 있습니다.
이 회사는 최근에 DEA의 1급 및 2급 약물 재배 및 제조 연간 운영 절차를 통과하여 운영 시작에 더욱 가까워졌습니다. 새로운 자금 조달 및 공급 계약이 진행 중인 가운데, Bright Green은 2025년에 강력한 성과를 예상하고 있습니다.
Bright Green (Nasdaq: BGXX) a signé une lettre d'intention pour fournir des extraits de marijuana approuvés par la DEA et des psychédéliques d'origine végétale à Benuvia Operations, un leader dans les cannabinoïdes pharmaceutiques et les molécules psychédéliques. Ce partenariat vise à produire des principes actifs pharmaceutiques (API) de qualité pharmaceutique cGMP fabriqués localement pour les marchés américains et mondiaux. Bright Green se positionne comme un fournisseur national de premier plan de matières premières végétales contrôlées par la DEA pour des médicaments à base de cannabinoïdes, psychédéliques et opioïdes aux États-Unis.
L'entreprise a récemment réussi les procédures opérationnelles annuelles de la DEA pour la culture et la fabrication de médicaments de Catégorie I et II, se rapprochant ainsi du début de ses opérations. Avec de nouveaux accords de financement et d'approvisionnement en cours, Bright Green prévoit une forte performance en 2025.
Bright Green (Nasdaq: BGXX) hat eine Absichtserklärung unterzeichnet, um von der DEA genehmigte Marihuana-Extrakte und pflanzenbasierte Psychedelika an Benuvia Operations, einen führenden Anbieter von pharmazeutischen Cannabinoiden und psychedelischen Molekülen, zu liefern. Diese Partnerschaft zielt darauf ab, inländisch hergestellte cGMP-arzneimittelgerechte Wirkstoffe (APIs) für US-amerikanische und globale Märkte zu produzieren. Bright Green positioniert sich als führender inländischer Anbieter von von der DEA kontrollierten pflanzenbasierten Rohstoffen für cannabinoid-, psychedelische und opioide Medikamente in den USA.
Das Unternehmen hat kürzlich die jährlichen Betriebsverfahren der DEA für den Anbau und die Herstellung von Betäubungsmitteln der Klassen I und II bestanden, was es ihm ermöglicht, näher an den Beginn der Betriebe zu rücken. Mit neuen Fundraising- und Lieferverträgen in der Pipeline erwartet Bright Green eine starke Leistung im Jahr 2025.
- Signed letter of intent to supply DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations
- Positioning as leading domestic supplier of DEA-controlled, plant-based raw materials for pharmaceutical industry
- Passed DEA's annual operational procedures for Schedule I & II drug cultivation and manufacturing
- New round of fundraising and supply agreements in progress
- Anticipating strong performance in 2025
- None.
This partnership between Bright Green and Benuvia Operations marks a significant development in the US pharmaceutical industry. It demonstrates a shift towards domestic production of Schedule I & II raw materials for pharmaceutical use, potentially reducing reliance on international sources. The collaboration leverages Bright Green's unique DEA approval and Benuvia's FDA registration and cGMP certification, creating a fully compliant supply chain for cannabinoid and psychedelic-based pharmaceuticals.
This move could accelerate drug development in these emerging therapeutic areas, potentially leading to new treatment options for various conditions. For investors, this partnership signals Bright Green's growing market position and could lead to increased revenue streams in the coming years, particularly as the company plans for strong performance in 2025.
This partnership represents a landmark shift in US drug policy implementation. By allowing Bright Green to supply DEA-controlled substances for pharmaceutical research and production, the government is facilitating legal, domestic production of previously restricted materials. This move aligns with a growing trend of re-evaluating drug policies, particularly around cannabinoids and psychedelics.
The agreement's compliance with GACP, GMP and DEA regulations sets a new standard for the industry. It could pave the way for more research and development in these areas, potentially leading to policy changes and expanded medical applications. For Bright Green, this positions them as a pioneer in a highly regulated but potentially lucrative market.
This partnership signals a potential boom in the US pharmaceutical cannabinoid and psychedelic market. With Bright Green's unique position as a DEA-approved supplier and Benuvia's established presence in pharmaceutical cannabinoids, we could see a significant increase in domestic production and research of these compounds. The global psychedelic drugs market is projected to reach
Investors should note that while this partnership shows promise, the market is still in its early stages and faces regulatory hurdles. However, Bright Green's DEA approval and this partnership could give them a competitive edge as the market develops. The company's plans for fundraising and additional supply agreements suggest a strategy for rapid growth, which could translate to increased market share and potential returns for investors.
GRANTS, NEW MEXICO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use.
This completely homegrown agreement signals Bright Green’s ability and commitment to supply US pharmaceutical partners with high quality organic materials. As part of the supply agreement proposed in the LOI, Benuvia intends to leverage Bright Green’s unique position to produce Schedule I & II raw materials in full compliance with Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and the DEA, all within the USA, to produce domestically manufactured cGMP pharmaceutical-grade Active Pharmaceutical Ingredients (“APIs”) for US and global markets.
Bright Green sees this as yet another step towards becoming the leading domestic supplier of DEA controlled, plant-based raw materials to produce cannabinoid, psychedelic and opioid based drugs in the USA. With a new round of fundraising and supply agreements in the works, Bright Green is positioned for a strong performance in 2025.
The Drug Enforcement Administration (DEA) just completed its annual operational procedures for all its Schedule I & II drug cultivation and manufacturing in July. Bright Green meets this high national standard and is now one step closer to beginning operations and supplying the pharmaceutical world with the materials it needs to innovate.
ABOUT BRIGHT GREEN CORPORATION
Bright Green is one of the few companies authorized by the US government and the New Mexico Board of Pharmacy to grow, manufacture, and sell, legally under federal and state law, Schedule I and II plant-based drugs for research, pharmaceutical applications, and affiliated export. Bright Green’s approval from the U.S. Drug Enforcement Administration gives them the opportunity to advance their vision of improving quality of life through the opportunities presented by cannabis and other plant based derived therapies and more. To learn more, visit www.brightgreen.us
ABOUT BENUVIA
Benuvia Operations, LLC is a pioneering leader in the research, development, and commercialization of innovative pharmaceutical products across a wide range of therapeutic areas. Benuvia is committed to improving patient outcomes through rigorous scientific study and quality manufacturing practices. With FDA registration, DEA licensing, and cGMP certification, Benuvia operates at the forefront of the pharmaceutical industry. Benuvia's flagship product, SYNDROS, is an FDA-approved medication used for the treatment of anorexia associated with weight loss in patients with AIDS and for managing chemotherapy-induced nausea and vomiting. To learn more, visit www.benuvia.com.
Media Inquiries & Investor Relations Contact
ir@brightgreen.us
FAQ
What is the recent partnership announcement for Bright Green (BGXX)?
What products will Bright Green (BGXX) supply to Benuvia Operations?
How does the Benuvia partnership affect Bright Green's (BGXX) market position?
What recent regulatory milestone has Bright Green (BGXX) achieved?
What is Bright Green's (BGXX) performance outlook for 2025?
